
BioLight Israeli Life Sciences Investments’ subsidiary, ViSci, has filed an investigational new drug (IND) application with the FDA to conduct a phase I/IIa clinical study with its treatment for glaucoma-a subconjunctival Latanoprost controlled-release insert.


.png)


